| Catalog | Description | Size | Price (USD) | Qty |
|---|---|---|---|---|
| GBM-2158-10MG | Pazopanib | 10mg | $84.00 | |
| GBM-2158-50MG | Pazopanib | 50mg | $252.00 |
| Bioassays Specification | |
| Bio-Activity | Multi-receptor tyrosine kinase inhibitor |
| Chemical Name | 5-[[4-[(2,3-Dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide |
| Function / Pharmacology | Inhibits multiple receptor tyrosine kinases including VEGFR1,2 and 3 (IC50s=10, 30, 47 nM respectively) and PDGFRα, β and c-Kit (IC50s=71, 84, 74 nM respectively) and others such as FGFR1. The drug targets both the tumor and endothelial cells in a mouse xenograft model of human multiple myeloma2. It reduces joint pain and inhibits cartilage degeneration in rodent osteoarthritis models3. VEGF inhibitors such as pazopanib have potential for treatment of neovascular age-related macular degeneration4 In clinical use for renal cell carcinoma5. |
| CAS# | 444731-52-6 |
| MW | 437.5 |
| Molecular Formula | C21H23N7O2S |
| Solubility | Soluble in DMSO (up to 16 mg/ml). |
| Supplied | powder |
| Storage as supplied | -20°C |
| Ship temp | Ambient |
| References | 1. R Kumar et al. Mol. Cancer Ther. 2007 6:2012 2. K Podar et al. Proc. Natl. Acad. Sci. USA 2006 103:19478 3. K Ma et al. Int. J. Biol. Sci. 2023 19:675 4. M Rami-Baraka and PK Kaiser Expert. Opin. Investig. Drugs 2009 18:637 5. A Comandone et al. Cancers (Basel) 2021 13:5896 |
| Antibody Specification | |
| Alternate Names | GSK-VEG10003; GW786034B |
| Protein Specification | |
| Purity | >98% |
| Bioassays Specification | |
| Bio-Activity | Multi-receptor tyrosine kinase inhibitor |
| Chemical Name | 5-[[4-[(2,3-Dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide |
| Function / Pharmacology | Inhibits multiple receptor tyrosine kinases including VEGFR1,2 and 3 (IC50s=10, 30, 47 nM respectively) and PDGFRα, β and c-Kit (IC50s=71, 84, 74 nM respectively) and others such as FGFR1. The drug targets both the tumor and endothelial cells in a mouse xenograft model of human multiple myeloma2. It reduces joint pain and inhibits cartilage degeneration in rodent osteoarthritis models3. VEGF inhibitors such as pazopanib have potential for treatment of neovascular age-related macular degeneration4 In clinical use for renal cell carcinoma5. |
| CAS# | 444731-52-6 |
| MW | 437.5 |
| Molecular Formula | C21H23N7O2S |
| Solubility | Soluble in DMSO (up to 16 mg/ml). |
| Supplied | powder |
| Storage as supplied | -20°C |
| Ship temp | Ambient |
| References | 1. R Kumar et al. Mol. Cancer Ther. 2007 6:2012 2. K Podar et al. Proc. Natl. Acad. Sci. USA 2006 103:19478 3. K Ma et al. Int. J. Biol. Sci. 2023 19:675 4. M Rami-Baraka and PK Kaiser Expert. Opin. Investig. Drugs 2009 18:637 5. A Comandone et al. Cancers (Basel) 2021 13:5896 |
| Antibody Specification | |
| Alternate Names | GSK-VEG10003; GW786034B |
| Protein Specification | |
| Purity | >98% |
